Bandelow, Borwin

[["dc.bibliographiccitation.firstpage","32"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","PSYCHOPHARMAKOTHERAPIE"],["dc.bibliographiccitation.lastpage","33"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Fiege, O."],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T08:47:19Z"],["dc.date.available","2018-11-07T08:47:19Z"],["dc.date.issued","2005"],["dc.identifier.isi","000227807100009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20924"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wissenschaftliche Verlag Mbh"],["dc.relation.issn","0944-6877"],["dc.title","Oculogyric crisis under aripiprazol in combination with fluoxetin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","948"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Canadian Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","952"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Tichauer, G. A."],["dc.contributor.author","Spath, C."],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:20:34Z"],["dc.date.available","2018-11-07T11:20:34Z"],["dc.date.issued","2001"],["dc.description.abstract","Objective: The association between separation anxiety in childhood and actual separation experiences during childhood has not yet been investigated in patients with panic disorder. Methods: In 115 patients with panic disorder with or without agoraphobia and in 124 control subjects without a history of psychiatric illness, we assessed separation anxiety during childhood, retrospectively, using DSM-IV and ICD-10 criteria and the Separation Anxiety Symptom Inventory (SASI). In addition, actual separation experiences from age 0 to 15 years were assessed, retrospectively. Results: A total of 22.6% of the patients and 4.8% of the Control subjects fulfilled both DSM-IV and ICD-10 criteria for childhood separation anxiety (chi(2) = 11.8; P < 0.0001). Further, 57.4% ofthepatients and 37.9% of the control subjects reported actual separation experiences during their childhood (chi(2) = 9. 09, P < 0.003). Separation anxiety and actual separation experiences, however, were independent of each other. Conclusion: These results suggest that separation anxiety during childhood is not a consequence of actual traumatic separation experiences in panic disorder patients."],["dc.identifier.isi","000173099800007"],["dc.identifier.pmid","11816316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55564"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Canadian Psychiatric Assoc"],["dc.relation.issn","0706-7437"],["dc.title","Separation anxiety and actual separation experiences during childhood in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neurosciences"],["dc.bibliographiccitation.lastpage","271"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schenk-Daprá, Bettina"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Müller, Peter"],["dc.contributor.author","Niedmann, Paul Dieter"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Rüther, Eckart"],["dc.date.accessioned","2017-09-07T11:44:42Z"],["dc.date.available","2017-09-07T11:44:42Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective The goal of this study was to identify adverse effects of the atypical neuroleptic clozapine on liver function and lipid metabolism. Methods Data which included serum levels of clozapine and its hepatic metabolite N-desmethyl clozapine were collected from medical records of patients treated with clozapine and controls. Results We identified a clozapine-associated marked elevation of plasma cholinesterase (ChE) with unchanged levels of AST, ALT or g-GT. ChE was correlated to the serum level of clozapine and even closer to N-desmethyl clozapine. For the total patient group we observed significant correlations of ChE with the body-mass index and body weight. However, clozapine-treated patients and controls did not differ with regard to body-mass index, triglycerides, and cholesterol. Conclusion We report for the first time a clozapine-associated and dose-dependent elevation of plasma ChE, which may be related to clozapine-associated effects on hepatic lipid metabolism or ChE enzyme induction."],["dc.identifier.doi","10.1007/pl00007544"],["dc.identifier.gro","3151720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8541"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","0940-1334"],["dc.title","Clozapine-associated elevation of plasma cholinesterase"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","831"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","837"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:09:47Z"],["dc.date.available","2018-11-07T11:09:47Z"],["dc.date.issued","2000"],["dc.description.abstract","Background. Research on basal HPA axis activity in patients with panic disorder showed inconsistent results. Methods. Basal total plasma, plasma free and salivary cortisol levels were compared in patients with panic disorder (n = 47) and in healthy individuals (n = 23). Correlations between these fractions were calculated. Results. All three basal cortisol fractions were significantly elevated in patients compared to controls. There were significant correlations between all three cortisol fractions. Conclusions. Nonsignificant differences between cortisol levels of patients and healthy controls in previous studies may have been due to inclusion of less severely ill patients or to small sample sizes (96 words)."],["dc.identifier.doi","10.1007/s007020070062"],["dc.identifier.isi","000088415100008"],["dc.identifier.pmid","11005547"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53083"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Salivary, total plasma and plasma free cortisol in panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","495"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.lastpage","500"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Sojka, Felicita"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T09:10:15Z"],["dc.date.available","2018-11-07T09:10:15Z"],["dc.date.issued","2006"],["dc.description.abstract","Background. - Earlier studies on the influence of pregnancy and postpartum period on the course of panic disorder have been inconsistent. The present study aims to quantify panic manifestations in these periods in large sample of women. Method. - Panic manifestations, including exacerbations and new manifestations of panic disorder, were assessed retrospectively in a sample of 128 women with panic disorder with or without agoraphobia, 93 of whom had had 195 pregnancies. Results. - Panic manifestations were fewer during pregnancy and more frequent in the postpartum period when compared with the control period. Women who had never been pregnant had significantly more panic manifestations than women with prior pregnancies. Breastfeeding and miscarriages did not have a significant effect. Women with postpartum panic reported more psychosocial stress events during this period. Conclusions. - Possible reasons for postpartum panic and the protective effects of pregnancy are discussed, including psychosocial or hormonal factors and other neurobiological changes. Postpartum panic coincides with a sudden drop of hormones after delivery. (c) 2006 Elsevier Masson SAS. All rights reserved."],["dc.identifier.doi","10.1016/j.eurpsy.2005.11.005"],["dc.identifier.isi","000241925900010"],["dc.identifier.pmid","16529913"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26446"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.relation.issn","0924-9338"],["dc.title","Panic disorder during pregnancy and postpartum period"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2749"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Neuroreport"],["dc.bibliographiccitation.lastpage","2752"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.date.accessioned","2018-11-07T10:33:14Z"],["dc.date.available","2018-11-07T10:33:14Z"],["dc.date.issued","2000"],["dc.description.abstract","An adaptive consequence of prolonged ethanol consumption is a compensatory up-regulation of NMDA receptors in certain brain areas. Taking into account that homocysteine and its breakdown products (i.e. homocysteic acid) are putative neurotransmitters and agonists at the NMDA receptor, the aim of this study was to assess the influence of levels of homocysteine on alcohol withdrawal seizures. Six patients with chronic alcoholism who suffered from withdrawal seizures had significantly higher levels of homocysteine on admission (84.7 +/- 29.8 mu mol/l) than patients (n = 26) who did not develop seizures (30.2 +/- 23.2 mu mol/l; U = 8.0, p = 0.0007). Furthermore, seizure patients had significantly lower levels of folate and significantly higher blood alcohol concentrations. Using a logistic regression analysis, withdrawal seizures were best predicted by a high homocysteine level on admission (P < 0.01; odds ratio = 1.05). Homocysteine levels on admission may be a useful screening method to identify patients at risk for withdrawal seizures. NeuroReport 11:2749-2752 (C) 2000 Lippincott Williams & Wilkins."],["dc.identifier.doi","10.1097/00001756-200008210-00028"],["dc.identifier.isi","000089003300036"],["dc.identifier.pmid","10976956"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44558"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0959-4965"],["dc.title","Plasma homocysteine is a predictor of alcohol withdrawal seizures"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Fentzahn, Evelyn"],["dc.contributor.author","Truemper, Patricia"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T11:03:29Z"],["dc.date.available","2018-11-07T11:03:29Z"],["dc.date.issued","2007"],["dc.description.abstract","Background To date, specific scales for the assessment of severity of somatoform disorders are still rare. Characteristic cognitive and behavioural domains, representing severity are not incorporated in the existing scales. Results with the novel quantification inventory for somatoform syndromes (QUISS) are presented in this paper. Methods The QUISS has been developed as a qualified severity scale for patients fulfilling diagnostic criteria according to DSM-IV or/and ICD-10. It was designed to be particularly suitable for application in clinical trials and for monitoring the efficacy of psychotherapy and pharmacotherapy. Not only number, severity and frequency of somatoform symptoms, but also common cognitive and behavioural domains of somatoform disorders have been included into this instrument. Both an 18-item patient- and observer-rated version are available taking about 20 min to complete. The questionnaire was applied to patients with somatoform disorder (N = 96), major depression (N = 24), and panic disorder (N = 16). Results The psychometric properties of the scale are satisfactory. The QUISS showed high objectivity (Cronbach's alpha = 0.90 for both versions; inter-scale correlations r = 0.64-0.88; p < 0.05), good test-retest- (r = 0.87; p < 0.05) and inter-rater-reliability (r = 0.89; p < 0.05). External validity (moderately high correlations of QUISS-T to SOMS 7T (r = 0.54), significant discrimination to major depression p < 0.05) was satisfactory. Factor structure revealed five relevant factors. Conclusions The QUISS could be a useful instrument in somatoform disorders for the assessment of syndrome severity and treatment outcome in scientific and clinical settings."],["dc.identifier.doi","10.1007/s00406-006-0700-4"],["dc.identifier.isi","000246262900005"],["dc.identifier.pmid","17203236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51628"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0940-1334"],["dc.title","The quantification inventory for somatoform syndromes MISS): a novel instrument for the assessment of severity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","175"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","187"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Seidler-Brandler, Ulrich"],["dc.contributor.author","Becker, Andreas"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T11:07:40Z"],["dc.date.available","2018-11-07T11:07:40Z"],["dc.date.issued","2007"],["dc.description.abstract","Background. A number of meta-analyses have led to contradictory results regarding the efficacy of the psychological and pharmacological treatment of anxiety disorders. The main reasons for these inconsistent results seem to be the inclusion of heterogeneous studies and influences of selection biases. We performed a meta-analysis, which only included studies using a direct comparison of pharmacological, psychological, or combined treatments. Method. Sixteen studies on panic disorder, six studies on social anxiety disorder, and two studies on generalized anxiety disorder have been analyzed. Effect sizes for differences between the different treatment modalities were calculated. Also, the effect sizes of the pre-post differences were calculated. Results. Pharmacological treatment, cognitive-behavioural treatment, and the combination of both treatment modalities all led to substantial improvement between pre- and post-treatment. Combined pharmacological and psychological treatment was superior to the monotherapies for panic disorder. For social anxiety disorder, there is only preliminary support for combined treatment. Due to lack of sufficient data, no final conclusions can be drawn for generalized anxiety disorder. Conclusions. While drug treatment and CBT showed equal efficacy, only in panic disorder the combination of pharmacological and psychological treatment was superior to either treatment alone. For the other anxiety disorders, the evidence for greater efficacy of combination treatment is still not sufficient due to lack of studies."],["dc.identifier.doi","10.1080/15622970601110273"],["dc.identifier.isi","000249360400003"],["dc.identifier.pmid","17654408"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52620"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Ltd"],["dc.relation.issn","1562-2975"],["dc.title","Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","169"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Psychiatry Research"],["dc.bibliographiccitation.lastpage","179"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Krause, Jan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:08:29Z"],["dc.date.available","2018-11-07T11:08:29Z"],["dc.date.issued","2005"],["dc.description.abstract","Patients with borderline personality disorder (BPD) were have not yet been compared with a healthy control group with regard to traumatic life events during childhood. The patients (n = 66) and controls (n = 109) were investigated using a comprehensive retrospective interview with 203 questions about childhood traumatic life events, parental attitudes, family history of psychiatric disorders and birth risk factors. The frequency of reports of traumatic childhood experiences was significantly higher in patients than in controls, including sexual abuse, violence, separation from parents, childhood illness, and other factors. On a 0- to 10-point \"severe trauma scale,\" patients had significantly more severe traumatic events (mean score = 3.86, SD = 1.77) than control subjects (0.61, SD = 0.93). Only four (6.1%) of the BPD patients, but 67 (61.5%) of the controls did not report any severe traumatic events at all. Compared with controls, patients described the attitude of their parents as significantly more unfavorable in all aspects. Patients reported significantly higher rates of psychiatric disorders in their families in general, especially anxiety disorders, depression, and suicidality. Among birth risk factors, premature birth was reported more often in BPD subjects. In a logistic regression model of all possible etiological factors examined, the following factors showed a significant influence: familial neurotic spectrum disorders, childhood sexual abuse, separation from parents and unfavorable parental rearing styles. The present data support the hypothesis that the etiology of BPD is multifactorial and that familial psychiatric disorders and sexual abuse are contributing factors. © 2005 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.psychres.2003.07.008"],["dc.identifier.isi","000228935500007"],["dc.identifier.pmid","15840418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0165-1781"],["dc.title","Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","31"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","MMW - Fortschritte der Medizin"],["dc.bibliographiccitation.lastpage","34"],["dc.bibliographiccitation.volume","148"],["dc.contributor.author","Bandelow, B."],["dc.contributor.author","Wolff-Menzler, C."],["dc.contributor.author","Wedekind, D."],["dc.contributor.author","Rüther, E."],["dc.date.accessioned","2021-06-01T10:49:00Z"],["dc.date.available","2021-06-01T10:49:00Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1007/BF03364531"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86128"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1613-3560"],["dc.relation.issn","1438-3276"],["dc.title","Wie lange muss mindestens behandelt werden?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]